Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies)

Leukemia Research
Christian RoseGFM (Groupe Francophone des Myélodysplasies)

Abstract

Iron chelation therapy (CT) improves survival in thalassemia major but its beneficial effects on survival in MDS patients remain uncertain. We analyzed, by multivariate analysis, survival and causes of deaths in 97 low or intermediate 1 IPSS patients regularly transfused as outpatients, chelated or not, who were included during a month period and followed for 2.5 years. 44 (45%) of patients were not chelated and 53 (55%) received CT, mainly with deferoxamine, for at least 6 months (median duration of chelation 36 months, range 6-131+). During the follow-up period, 66 of the 97 patients died, including 51% and 73% of chelated and non-chelated patients, respectively. Median overall survival was 53 months and 124 months in non-chelated and in chelated patients (p<0.0003). Causes of death did not significantly differ between the two groups (p=0.51). In multivariate Cox analysis, adequate chelation was the strongest independent factor associated with better OS. Iron chelation therapy appears to improve survival in heavily transfused lower risk MDS, but prospective randomized studies are required to confirm our findings, and to determine more precisely the mechanisms of this potential survival benefit.

References

Feb 5, 1981·The New England Journal of Medicine·A I SchaferH F Bunn
Sep 1, 1994·The New England Journal of Medicine·G M BrittenhamJ W Harris
May 1, 1993·The Journal of Clinical Investigation·J R BoelaertY J Schneider
Sep 1, 1995·Pediatric Hematology and Oncology·P ValleU Ramenghi
Aug 1, 1996·British Journal of Haematology·P D JensenJ Ellegaard
Mar 4, 2000·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·N L HarrisC D Bloomfield
Sep 28, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Luca MalcovatiMario Cazzola
Oct 6, 2006·The New England Journal of Medicine·Alan ListUNKNOWN Myelodysplastic Syndrome-003 Study Investigators
Mar 30, 2007·European Journal of Haematology·Masaaki TakatokuUNKNOWN Japanese National Research Group on Idiopathic Bone Marrow Failure Syndromes
Oct 18, 2007·Blood·Sophie ParkUNKNOWN GFM group (Groupe Francophone des Myélodysplasies)
Jan 1, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Timothy R AsmisUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Sep 4, 2008·American Journal of Hematology·John M Bennett, UNKNOWN MDS Foundation's Working Group on Transfusional Iron Overload

❮ Previous
Next ❯

Citations

Oct 13, 2010·Annals of Hematology·Norbert Gattermann, Eliezer A Rachmilewitz
Feb 19, 2013·Annals of Hematology·Massimo Breccia, Giuliana Alimena
Mar 1, 2012·International Journal of Hematology·Kumiko YagisawaYoshifusa Aizawa
Mar 13, 2012·International Journal of Hematology·Shohei KikuchiJunji Kato
Sep 3, 2011·PloS One·Valeria SantiniMaria Domenica Cappellini
Jan 1, 2010·Mediterranean Journal of Hematology and Infectious Diseases·Francesco D'AlòMaria Teresa Voso
Feb 11, 2014·Best Practice & Research. Clinical Haematology·David P Steensma, Norbert Gattermann
Jul 30, 2014·Hematology/oncology Clinics of North America·John B Porter, Maciej Garbowski
Sep 4, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P FenauxUNKNOWN ESMO Guidelines Working Group
Jun 14, 2014·International Journal of Hematology·Bor-Sheng KoHwei-Fang Tien
Dec 20, 2011·Expert Opinion on Drug Metabolism & Toxicology·Renzo GalanelloRaffaella Origa
Mar 17, 2016·South Asian Journal of Cancer·Sachi Jain Taran, Rakesh Taran
Jun 25, 2010·Leukemia Research·Moshe MittelmanDrorit Neumann
Feb 2, 2010·Blood Reviews·Pierre Fenaux, Christian Rose
Oct 20, 2015·Drugs & Aging·Sonja BurgstallerReinhard Stauder
Jan 1, 2014·British Journal of Haematology·Sally B KillickUNKNOWN British Committee for Standards in Haematology
Apr 5, 2016·Pharmacogenomics·Jessica CusatoAntonio D'Avolio
Aug 15, 2015·Journal of Comparative Effectiveness Research·Amer M ZeidanAmy J Davidoff
Dec 7, 2013·Clinical Lymphoma, Myeloma & Leukemia·Rami S KomrokjiAlan F List
Apr 12, 2013·Blood·Pierre Fenaux, Lionel Adès
Jun 10, 2010·Clinical Journal of Oncology Nursing·Sandra E Kurtin, Erin P Demakos
Apr 22, 2016·Expert Review of Hematology·Morena CairaCorrado Girmenia

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.